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At a Glance Commentary:  
Scientific Knowledge on the Subject: The currently used dose of 10 mg rifampin/kg for the 
treatment of drug sensitive tuberculosis is probably too low. Data in vitro, in mice and in 
humans indicate that higher doses of rifampin may shorten the duration of treatment and 
decrease the emergence of resistance. 
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What This Study Adds to the Field:  
Higher doses of rifampin up to 35 mg/kg were safe and well tolerated for two weeks. The 
higher doses of rifampin achieved up to 10-fold higher average exposures in plasma. There is 
an indication of increased efficacy in the higher dosing groups because of a greater 
estimated fall in bacterial load. These findings offer evidence for a definitive answer to the 
question what the right dose of rifampin is.  
 
This article has an online data supplement, which is accessible from this issue's table of 
content online at www.atsjournals.org" 
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ABSTRACT  
Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on 
pharmacokinetic, toxicity and cost considerations. Available data in mice and humans 
showed that an increase in dose may shorten the duration of tuberculosis treatment.  
Objectives: To evaluate the safety and tolerability, the pharmacokinetics and the extended 
early bactericidal activity of increasing doses of rifampin. 
Methods: Patients with drug-susceptible tuberculosis were enrolled into a control group of 8 
patients receiving the standard dose of 10 mg/kg rifampin, followed by consecutive 
experimental groups with 15 patients each receiving rifampin 20 mg/kg, 25 mg/kg, 30 mg/kg 
and 35 mg/kg, respectively, for 14 days. In all patients isoniazid, pyrazinamide and 
ethambutol were added in standard doses for the second 7 days of treatment. Safety, 
pharmacokinetics of rifampin, and fall in bacterial load were assessed. 
Measurements and Main Results: Grade 1 and 2 adverse events were equally distributed 
between the five dose groups; there were 5 grade 3 events of which 1 was a possibly related 
hepatotoxicity.  Areas under the time-concentration curves and peak serum concentrations 
of rifampin showed a more than proportional increase with dose. The daily fall in bacterial 
load over 14 days was 0.176, 0.168, 0.167, 0.265, and 0.261 log10CFU/ml sputum in the 10, 
20, 25, 30 and 35 mg/kg groups respectively. 
Conclusions: Two weeks of rifampin up to 35 mg/kg was safe and well tolerated. There was a 
non-linear increase in exposure to rifampin without an apparent ceiling effect and a greater 
estimated fall in bacterial load in the higher dosing groups. (ClinicalTrials.gov number 
NCT01392911) 
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Word count abstract: 258 
 
INTRODUCTION  
Rifampin is one of the pivotal drugs for the treatment of tuberculosis. The US Food and Drug 
Administration approved rifampin in 1971 and several trials showed that rifampin 
containing-regimens were very effective: in combination with pyrazinamide, it became 
possible to shorten the duration of treatment to six months.(1) Six-month rifampin-
containing regimens are now the standard of care and recommended by national and 
international bodies including the American Thoracic Society and the World Health 
Organization. Virtually all of the studies that underpin these recommendations used a dose 
of 10 mg rifampin/kg.(2) A dose finding study with an assessment of the maximum tolerated 
dose(3) was never performed.  The recommended dose was chosen on the basis that it was 
effective at the lowest cost and limited by fear of adverse effects. 
 
There is an accumulating body of evidence that suggest that higher doses of rifampin may be 
more effective and lead to significant shortening of the duration of tuberculosis treatment. 
In vitro experiments in a pharmacokinetic-pharmacodynamic model of tuberculosis showed 
that higher doses of rifampin kill the bacteria more rapidly and prevent the emergence of 
resistance to rifampin(4). Mouse experiments showed increased killing of bacteria and 
enhanced sterilizing activity with higher doses, resulting in a significant shortening of 
treatment duration.(5-7) Additionally, an estimation of maximum tolerated dose in mice was 
shown to be 160 mg rifampin/kg(7). Studies of monotherapy with rifampin in tuberculosis 
patients demonstrated that a moderate increase in the dose of rifampin leads to a steeper 
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fall of bacterial load over time.(8-10) A systematic review of 14 randomized controlled trials 
that evaluated higher doses up to 20 mg rifampin/kg in humans, most of them performed 
before 1980, suggests that higher doses of rifampin result in improved culture conversion 
rates.(11) A trial in pulmonary tuberculosis patients in Indonesia comparing 450mg rifampin 
(10 mg/kg) to 600 mg/kg (13 mg/kg) rifampin showed a nonlinear, more than proportional 
increase of pharmacokinetic exposure.(12)  
 
The adverse effects of rifampin at the standard dose are well known, because of years of 
worldwide use since its int oduction.(13) Yet, the relationship between dose and adverse 
events is not well established and may be either toxic with a clear relation or idiosyncratic 
without such a relation.(14) There have been trials and case series that used higher doses of 
rifampin in tuberculosis and other infections such as brucellosis, leishmaniasis, Legionnaires’ 
disease, and bone and joint infections(2, 15-19) without severe adverse effects. Some 
events, such as the flu like syndrome are likely related to intermittent dosing.(20) 
 
If increasing rifampin may be more effective and could shorten therapy there is an urgent 
need to know the optimum dose. We performed a study in tuberculosis patients, therefore, 
to establish the maximum tolerated dose, to assess the incidence and severity of adverse 
events, to describe the pharmacokinetics and to measure the bactericidal effect of higher 
doses of rifampin.  
 
Some of the results of these studies have been previously reported in the form of an 
abstract. (21) 
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METHODS 
Patients  
Adults (18 to 65) with newly diagnosed, previously untreated, sputum smear-positive 
uncomplicated pulmonary tuberculosis and with no medical contraindications (see Table E1 
in the online data supplement) were included in the study. For HIV positive subjects a CD4 
count of ≥350 cells was an additional inclusion criterion. Patients were hospitalized in one of 
two study sites in Cape Town, South Africa. 
Study design   
We performed an open-label phase II multiple dose ranging study to evaluate safety, 
tolerability, pharmacokinetics and extended early bactericidal activity of increasing doses of 
rifampin.  All patients received a specified dose of rifampin for 14 days, given in 
monotherapy for the first 7 days and supplemented with standard doses of isoniazid 5 
mg/kg, pyrazinamide 25-30 mg/kg and ethambutol 15-20 mg/kg for the last 7 days. The 
patients then continued standard tuberculosis treatment (Figure 1) and had visits at 3 and 12 
weeks for clinical assessment and sputum culture for susceptibility testing.  
The first 8 patients were enrolled in a control cohort receiving 10mg rifampin/kg. 
Subsequently, patients were enrolled in consecutive intervention cohorts of 15 patients 
each. The first cohort received rifampin at a dose of 20 mg/kg. The second cohort received 
25 mg rifampin/kg, the third 30 mg rifampin/kg and the last cohort received 35 mg 
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rifampin/kg.  Of note, the consecutive dose increases for rifampin were relatively small, 
considering the non-linear pharmacokinetics of rifampin, which means that an increase in 
dose may result in an unpredictable, disproportionally larger increase in exposure.(22)  
After completion of follow-up by all subjects in each cohort, the Trial Steering Committee, 
reviewed all of the safety data for the cohort before the first patient in the next cohort was 
enrolled. Two subjects experiencing a grade 3 adverse event assessed as probably or 
definitely related to administration of high dose rifampin, or one subject experiencing a 
grade 4 or 5 adverse event assessed as definitely related to rifampin, would lead to a 
meeting of the Trial Steering Committee to discuss the continuation or termination of the 
study.(23) 
The study protocol was approved by local ethical review boards and by the Medical Control 
Council of South Africa and was conducted according to Good Clinical Practice standards. All 
patients provided written informed consent before enrolment in the study. 
The innovative design of this study differs from a classical “early bactericidal activity” study 
intended for comparison.  
Drug management 
During the 7 days of rifampin monotherapy, patients received rifampin administered as 
capsules Rifadin® (150 mg, 300 mg and /or 600 mg) from Sanofi-Aventis. Combination 
therapy of rifampin, isoniazid, pyrazinamide and ethambutol during the subsequent 7 days 
was administered in the form of the fixed dose combination (FDC) Rifafour® e-275 from 
Sanofi-Aventis, containing 150 mg rifampin, 75 mg isoniazid, 400 mg pyrazinamide and 
275 mg ethambutol per tablet. The subjects in the control group received only standard 
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Rifafour® e-275 treatment. The subjects in the other dosing groups received additional 
Rifadin® to reach the same pre-defined rifampin dose as administered in the monotherapy 
period. The exact amount of Rifafour®e-275 tablets and Rifadin® capsules was dependent on 
the dosing group of the patient and the patient’s weight before start of the study. Daily 
treatment bottles for all 14 days were prepared in advance and checked by pharmacists or 
site staff members who were licensed for dispensing.  
 
Safety and tolerability  
The primary objective of this study was to assess the maximum tolerated dose, which is 
defined as the dose below that producing unacceptable but reversible toxicity. Tolerability is 
an aspect of safety and used to indicate how well a patient is able to endure treatment such 
that adverse events do not result in the discontinuation of treatment(3). 
Symptoms assessments, physical examination, including vital signs, were performed on a 
daily base. Haematological, renal and liver function tests, glucose, uric acid and urinalysis 
and electrocardiography were scheduled at baseline and days 1, 3, 6, 10, 14 and 21 with 
appropriately narrow window periods. Adverse events were graded according to the US 
National Institute of Health Common Terminology Criteria for Adverse Events 4.0.(24) 
Patients with serious adverse events were followed up until resolution of the event. Events 
were assessed as unrelated, possibly or definitely related by site investigators (see Table E2 
in the online data supplement). 
Pharmacokinetics   
Blood samples were taken on day 7 and day 14 with a standardized meal for a full 
pharmacokinetics curve. Total (protein-bound plus unbound) plasma concentrations of 
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rifampin were measured at the Department of Pharmacy of the Radboud University Medical 
center, Nijmegen, the Netherlands, using a validated Ultra Performance Liquid 
Chromatography method with ultraviolet detection, derived from a previously described 
assay.(12) Noncompartmental pharmacokinetic analysis was performed with Winnonlin 
version 5.3 (Pharsight Corp., Mountain View, California US) to yield pharmacokinetic 
parameters, including the area under the plasma concentration-time curve (AUC0-24h or total 
exposure) and highest observed plasma concentration (Cmax), as described before.(12)  
 
Antimycobacterial activity 
Spot sputum samples were collected before enrolment, at day 19 and after 12 weeks. The 
samples were prepared for direct microscopy, stained with the auramine O method and 
presence of acid fast bacilli was scored using the IUATLD/WHO grading. Pooled overnight (16 
hours) samples were collected at baseline, daily to day 7, days 9 and 14. Each sample was 
diluted and cultured in quadruplicate on selective Middlebrook 7H11 agar plates.  Counts of 
colony forming units (CFU) were done after a minimum of 21 days of incubation to assess 
the fall of CFU over time.(25, 26) In addition, the samples were processed for culture in 
liquid broth medium according to the mycobacterial growth indicator tube (Bactec MGIT960) 
system. Time-to-positivity (TTP) was determined for each sample to assess the change in TTP 
over time. The remainder of the baseline samples were processed to determine 
susceptibility tests and an Accuprobe identification (Gen-Probe®) test was carried out to 
confirm presence of M. tuberculosis complex.  All microbiological testing was performed 
in the Department of Medical Biochemistry, Faculty of Medicine and Health Sciences, 
Stellenbosch University, Cape Town, South Africa.  
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Statistical analysis  
This was a descriptive study with no inferential statistics or hypothesis testing. The planned 
sample size of 15 patients in each group is in keeping with other trials of this type and 
accounts for the site conservative estimate of 3 dropouts per group.(3) Safety was expressed 
as incidence of adverse events by severity and relatedness. The AUC0-24h and Cmax of 
rifampin at days 7 and 14 were presented as geometric means by study group. The 
distribution of TTP on MGIT was positively skewed with log-transformed TTP more closely 
following a symmetric normal distribution. Mixed effects models with visit day as a discrete 
random effect were used to estimate the mean logCFU and logTTP in each treatment arm at 
each visit to describe the data. LogCFU of 1 or TTP of 42 days was used for negative cultures 
in this analysis. We found an unexpectedly high number of negative cultures for the short 
treatment duration. These data points would usually be excluded with standard regression 
methods due to the quantitative measure of logCFU or TTP being below or above the limit of 
detection. In order to include these censored observations, Tobit regression(27) was used to 
estimate the 14-day early bactericidal activity, accounting for negatives cultures using a 
lower limit of detection censoring for logCFU of 1 and an upper limit for TTP of 42 days. 
Separate models were fitted for each patient with parameter estimates summarised by 
treatment group using a random effects model accounting for within- and between- patient 
variability. Linear regression was used to explore the relationship between 14-day early 
bactericidal activity and each of actual dose received in mg, actual dose received in mg/kg 
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and exposures achieved (AUC0-24 and Cmax) comparing models using the proportion of 
variation explained, R
2
. 
 
 
RESULTS 
Patients 
A total of 68 culture positive pulmonary tuberculosis patients were recruited between June 
2011 and April 2012 with the last patient completing follow-up in August 2012. Patient 
characteristics are shown in Table 1.  
Safety/tolerability 
The stopping criteria were not met and the Trial Steering Committee recommended that the 
trial continued after data safety review at the end of each cohort. None of the patients 
discontinued or were withdrawn from the study. There were a total of 163 adverse events: 
128 grade 1, 30 grade 2, and 5 grade 3 adverse events. No grade 4 and 5 adverse events 
occurred. 53 adverse events were unrelated to rifampin, 102 were “possibly” related and 8 
were assessed to be “definitely” related to rifampin (Table 2).  
The most common adverse events related to monotherapy with rifampin were abdominal 
pain, vomiting, headache, and pruritus. The most common adverse events related to the 
combination treatment with rifampin, isoniazid, pyrazinamide and ethambutol were 
vomiting, headache, hyperuricaemia, pain in the extremities and pruritus. These adverse 
events occurred in all groups and were not attributable to a specific dose group.  
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Pharmacokinetics 
The average AUC0-24 and Cmax values of rifampin at day 14 are presented in Table 3. Upon 
doubling the dose of rifampin from 10 mg/kg to 20 mg/kg, the geometric mean AUC0-24  of 
rifampin increased more than four-fold, which reflects a more than dose-proportional 
increase of exposure with the dose. No ceiling in rifampin AUC0-24 or flattening of the 
relationship between dose administered and AUC0-24 achieved was observed. Strong 
increases in average rifampin Cmax with the dose were also observed (Table 3). Of note, 
large interindividual variability in  AUC0-24h and Cmax was observed (Table 3 and Figure 2), yet 
the minimum exposure recorded in each group (either in terms of AUC0-24h or Cmax) increased 
with the dose administered.   
Antimycobacterial activity  
One patient in the 20 mg/kg group was negative on solid media at all but one sample and 
these data were therefore removed from all analyses. The fall in bacterial load in sputum 
over time expressed as CFU and TTP is summarized in Figure 3. The highest doses of 30 and 
35 mg/kg show highest 14-day early bactericidal activity on both CFU and TTP (Figure 4).  
There was no clear biphasic curve from days 7-14 after which the other drugs, including 
isoniazid were added. At 14 days, 8 of 14 patients in the 35mg/kg group were culture 
negative on solid media as compared to 3 of 8 in the control group, 5 of 14 in the 20 mg/kg 
group, 0 of 15 in the 25 mg/kg and 2 of 15 in the 30 mg/kg group. 
AUC0-24h at day 14 was a better predictor of 14-day early bactericidal activity on CFU 
(R
2
=0.12) than dose in mg/kg received (R
2
=0.06) or the dose in mg (R
2
=0.05), although the 
proportion of explained variance was low. AUC0-24h was a marginally better predictor of 14-
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day early bactericidal activity on TTP (R
2
=0.19) than dose in mg/kg received (R
2
=0.18) or the 
dose in mg (R
2
=0.12). 
 
 
DISCUSSION 
This study shows that doses of rifampin that are considerably higher than the standard dose 
are safe and well tolerated. As accumulating evidence indicates that higher doses of and 
increased exposures to rifampin are more efficacious in tuberculosis treatment, (5-7, 10, 11, 
28, 29) we believe that this finding may change the landscape of treatment for drug 
susceptible tuberculosis and may permit shortening of the duration of treatment, as rifampin 
is a very strong sterilizer. In addition, there is evidence that an important driver behind the 
emergence of multidrug-resistant tuberculosis is low exposures of especially rifampin caused 
by inter-individual pharmacokinetic variability. (4, 30, 31) The current standard dose of 
rifampin used in the last 40 years is probably considerably too low in many patients.  
  
The primary objective of this study was to estimate the maximum tolerated dose of rifampin 
and it was significant that dose-limiting toxicities were not found at the highest administered 
dose of 35 mg/kg daily. Higher doses than 35 mg/kg were not planned before the study, as 
very high exposures to rifampin were anticipated at this dose and the study did not have 
unrestricted funding.  
The pharmacokinetic behaviour of rifampin over the range of increasing doses was more 
than dose-proportional, “super-proportional”. The average AUC0-24 at 35 mg/kg was almost 
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10-fold higher than the average exposure at 10 mg/kg rifampin. This phenomenon was 
previously described in other studies for lower doses.(12, 22) We did not observe a ceiling 
effect as was reported in the pharmacokinetics of one of the other promising rifamycins, 
rifapentine.(32) Importantly, apart from average exposures, the lowest observed AUC0-24h 
and Cmax values also increased, with almost every dose step (Table 3 and Figure 2). This is 
what we aimed for, as it is probably the lowest exposures that cause treatment failures and 
relapses thereby preventing treatment shortening. In addition, these low exposures may 
favor the emergence of resistance.(4, 30, 31) We showed, however, that there was a large 
inter-individual variation in pharmacokinetics (Figure 2). This is a warning for further studies 
of high doses of rifampin, as individual exposures may be much higher than our observed 
means. This may have a beneficial effect in terms of efficacy, but may also cause an 
increased risk of toxicity. 
There was a greater estimated fall in bacterial load in the higher dosing groups dose as 
measured by a larger fall in CFUs over time and by a more rapid increase in TTP over time.  
This study was not powered for efficacy and these differences were not statistically 
significant. Although this result is encouraging, the finding may not necessarily indicate 
increased efficacy in terms of treatment failure and relapse, the definitive patient-relevant 
outcomes and phase III endpoints. In mouse models, however, there is evidence that higher 
doses of rifampin sterilize and cure the mice in a shorter period of time.(5-7) Additionally, in 
a recent clinical trial in Indonesian tuberculous meningitis patients higher doses of rifampin 
(around 13 mg/kg intravenously as compared to around 10 mg/kg orally) led to a decreased 
6 months mortality of roughly 50 %.(33) 
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By design, small numbers of patients selected on the basis of very strict criteria were treated 
for only a short period of time with higher doses of rifampin. Therefore, our findings need to 
be confirmed in longer phase II studies with less narrow inclusion criteria and adequate 
patients numbers before being tested in a phase III study. Currently, two studies have 
started with this objective. The first randomized controlled trial has recently finished 
enrolment (ClinicalTrials.gov NCT00760149) and compared a control group with the 
standard tuberculosis regimen with two groups of 15 mg rifampin/kg and 20 mg rifampin/kg 
combined with isoniazid, pyrazinamide and ethambutol for two months in groups of 50 
patients each. The second study with a multi arm multi stage (MAMS) design performed 
within the PanACEA consortium (ClinicalTrials.gov  NCT01785186) compares a standard 
control group with a group on 20 mg rifampin/kg combined with moxifloxacin, isoniazid and 
pyrazinamide, a group with 20 mg rifampin/kg combined with the new compound SQ109(34) 
and isoniazid and pyrazinamide, and a group with 35 mg rifampin/kg combined with 
isoniazid, pyrazinamide and ethambutol for three months. A further two month study is 
evaluating 15 mg rifampin/kg and 20 mg rifampin/kg in Peru (ClinicalTrials.gov 
NCT01408914). Depending on the results of these trials, we are planning to extend the study 
in this paper and increase the dose until the actual maximum tolerated dose is reached.  
In conclusion, higher doses of rifampin up to 35 mg/kg were safe and well tolerated for two 
weeks. The higher doses of rifampin achieved up to 10-fold higher average exposures in 
plasma, due to nonlinear “super-proportional” pharmacokinetic behaviour. The greater 
estimated fall in bacterial load measured by CFUs and TTP suggests an increased efficacy in 
the higher dosing groups supporting the idea that this critical drug is being administered at 
too low a dose. With the results of phase IIB studies currently underway that further 
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examine these higher dose, we should look forward to a pivotal phase III trial to definitely 
answer the question what the right dose of rifampin is. 
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                            All                             10 mg                         20 mg                    25 mg                       30 mg                           35 mg                                                          
                              Subjects                       RIF/kg                         RIF/kg                   RIF/kg                        RIF/kg                         RIF/kg                                                                                         
__________________________________________________________________________________________ __________                                           
                                                                                                                                                   
N                                  68                                8                               15                          15                               15                               15    
 
Age (yr)                                                                                                                                                                                                                                                                           
 Median                     30.5                             27.5                         27.0                        25.0                        40.0                              37.0                                                          
 Range                      18-59                           19-49                       18-46                     19-46                     19-59                           21-59                                                            
 
Weight (kg)                                                                                                                                                                                                                                                                                     
 Median                      53.6                            56.9                         52.5                         52.8                        54.0                              57.0                                                         
Range                      40.2-84.2                   46.8-64.9                41.8-62.7                 40.2-67.9               45.7-84.2                   40.5-74.0                                                          
                                                                                                                                                                                                                                                                                             
Body-Mass Index (kg/m^2)                                                                                                                                                                                                                                                                                    
 Median                      19.4                             20.5                        18.4                          19.3                        20.9                            19.5                                                         
 Range                      14.7-30.9                   15.8-26.3               16.8-26.2                 15.1-25.2              16.4-30.9                    14.7-25.2    
 
Male sex no.              48 (71)                         6 (75)                     11 (73)                     10 (67)                   11 (73)                       10 (67)                  
 
Race –no (%)                                                                                                                                                  
 Black                           28 (41)                        3 (38)                      7 (47)                        4 (27)                    9 (60)                          5 (33)                                           
 Coloured                    40 (59)                        5 (63)                      8 (53)                       11(73)                    6 (40)                         10  (67)                      
  
HIV-positive (%)          1(1,5)                          1 (13) 
 
Baseline log10CFU/ml median  
            (range)                                                  4.88                        4.00                          5.39                            4.58                       4.39
                                    (2.15-5.85)           (negative*-5.82)          (3.70-6.38)               (2.68-6.25)         (2.86-5.82) 
Baseline TTP / days median                        6.04     7.35  6.75  8.08                 8.22 
             (range)              (4.15 - 12.17)              (4.44-13.33)             (5.00-10.69)           (4.81-13.46)        (4.75-20.04) 
 
Table1. Demographic and baseline characteristics at inclusion. * One patient on 20mg/kg group was negative on solid 
media at all but one visit and their data was therefore removed from all analyses.  
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Group Total Grade 1 Grade 2 Grade 3 * 
Relatedness  Possibly 
related 
Related Possibly 
related 
Related Possibly 
related 
Related 
10 mg/kg 
(control) 
7 0 0 0 0 0 0 
20 mg/kg 
RIF 
39 21 1 4 0 2 0 
25 mg/kg 
RIF 
24 11 2 2 0 0 0 
30 mg/kg 
RIF 
39 21 3 4 0 1 0 
35 mg/kg 
RIF 
54 27 2 9 0 0 0 
Total 
 
163 80 8 19 0 3 0 
 
Table 2. Possibly related and definitely related adverse events per grade and per dose group *Among the grade 3 
events there was a case of transient hyperkalemia of 6.1 mmol/L  in the 20 mg/kg RIF group that reoccurred in 
the same patient in week 3 (counted as two events). Potassium values normalized with no specific measures 
and no ECG changes were recorded. In the 30 mg/kg RIF group there was one grade 3 unrelated pleural 
effusion and a possibly related elevation of transaminase more than five times the upper limit of normal, which 
normalized spontaneously after repeat measurements. No grade 4 or grade 5 events were observed.  
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Group AUC0-24h (h*mg/L) * Cmax (mg/L) # 
10 mg/kg (control)  26.3  (21.3 – 40.9)    7.4   (6.1 – 9.9) 
20 mg/kg 113    (77.5 – 162)  21.6  (16.0 – 31.9) 
25 mg/kg 135    (91.5 – 228)  25.1  (16.3 – 34.6) 
30 mg/kg 190    (84.7 – 436) 33.1  (17.6 – 55.8) 
35 mg/kg 235    (166 – 321)  35.2  (28.6 - 44.2) 
 
Table 3. Steady state PK of RIF (day 14) Geometric means and range *AUC0-24h : area under the time versus concentration 
curve up to 24 h post dose, Cmax: peak plasma concentration 
  
#
  Serial venous blood samples were taken just prior to and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours after the 
investigational products were taken under direct supervision and with  a standardized meal 
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Legends Figures 
 
Figure 1. Schematic overview of the study design 
In each study group, monotherapy of rifampin for 7 days was administered using Rifadin® from Sanofi-Aventis 
in 150 mg capsules, 300 mg tablets or 600 mg tablets. The combination of capsules and tablets for each patient 
was adjusted to achieve the correct dose by weight. In the subsequent period of 7 days, patients received a 
fixed dose combination tablet Rifafour e-275, containing 150 mg rifampin, 75 mg isoniazid, 400 mg 
pyrazinamide and 275 mg ethambutol, combined with additional rifampin (i.e. Rifadin) to reach the same 
pre-defined rifampin dose in mg/kg as administered in the monotherapy period. Starting from day 15 the 
patients were administered Rifafour e-275 only. All study medication was taken in the morning with a light 
breakfast and a glass of water. Administration of tuberculosis drugs was witnessed by site staff and a hand-and-
mouth procedure was performed to check for drug intake at every occasion.  
 
 
Figure 2. Distribution of exposure to rifampin (AUC0-24h) at day 14 in the various rifampin 
dosing groups . The reference line mimics a linear relationship. 
 
 
Figure 3. Fitted estimates of differences from mean baseline log10 CFU (upper panel) and 
log10TTP/ml (lower panel) by visit and treatment arm 
 
Figure 4. Early bactericidal activity of rifampin based on CFU (upper panel) and TTP (lower 
panel) per day  
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ABSTRACT  
Rationale: Rifampin at a dose of 10 mg/kg was introduced in 1971 based on 
pharmacokinetic, toxicity and cost considerations. Available data in mice and humans 
showed that an increase in dose may shorten the duration of tuberculosis treatment.  
Objectives: To evaluate the safety and tolerability, the pharmacokinetics and the extended 
early bactericidal activity of increasing doses of rifampin. 
Methods: Patients with drug-susceptible tuberculosis were enrolled into a control group of 8 
patients receiving the standard dose of 10 mg/kg rifampin, followed by consecutive 
experimental groups with 15 patients each receiving rifampin 20 mg/kg, 25 mg/kg, 30 mg/kg 
and 35 mg/kg, respectively, for 14 days. In all patients isoniazid, pyrazinamide and 
ethambutol were added in standard doses for the second 7 days of treatment. Safety, 
pharmacokinetics of rifampin, and fall in bacterial load were assessed. 
Measurements and Main Results: Grade 1 and 2 adverse events were equally distributed 
between the five dose groups; there were 5 grade 3 events of which 1 was a possibly related 
hepatotoxicity.  Areas under the time-concentration curves and peak serum concentrations 
of rifampin showed a more than proportional increase with dose. The daily fall in bacterial 
load over 14 days was 0.176, 0.168, 0.167, 0.265, and 0.261 log10CFU/ml sputum in the 10, 
20, 25, 30 and 35 mg/kg groups respectively. 
Conclusions: Two weeks of rifampin up to 35 mg/kg was safe and well tolerated. There was a 
non-linear increase in exposure to rifampin without an apparent ceiling effect and a greater 
estimated fall in bacterial load in the higher dosing groups. (ClinicalTrials.gov number 
NCT01392911) 
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INTRODUCTION  
Rifampin is one of the pivotal drugs for the treatment of tuberculosis. The US Food and Drug 
Administration approved rifampin in 1971 and several trials showed that rifampin 
containing-regimens were very effective: in combination with pyrazinamide, it became 
possible to shorten the duration of treatment to six months.(1) Six-month rifampin-
containing regimens are now the standard of care and recommended by national and 
international bodies including the American Thoracic Society and the World Health 
Organization. Virtually all of the studies that underpin these recommendations used a dose 
of 10 mg rifampin/kg.(2) A dose finding study with an assessment of the maximum tolerated 
dose(3) was never performed.  The recommended dose was chosen on the basis that it was 
effective at the lowest cost and limited by fear of adverse effects. 
 
There is an accumulating body of evidence that suggest that higher doses of rifampin may be 
more effective and lead to significant shortening of the duration of tuberculosis treatment. 
In vitro experiments in a pharmacokinetic-pharmacodynamic model of tuberculosis showed 
that higher doses of rifampin kill the bacteria more rapidly and prevent the emergence of 
resistance to rifampin(4). Mouse experiments showed increased killing of bacteria and 
enhanced sterilizing activity with higher doses, resulting in a significant shortening of 
treatment duration.(5-7) Additionally, an estimation of maximum tolerated dose in mice was 
shown to be 160 mg rifampin/kg(7). Studies of monotherapy with rifampin in tuberculosis 
patients demonstrated that a moderate increase in the dose of rifampin leads to a steeper 
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fall of bacterial load over time.(8-10) A systematic review of 14 randomized controlled trials 
that evaluated higher doses up to 20 mg rifampin/kg in humans, most of them performed 
before 1980, suggests that higher doses of rifampin result in improved culture conversion 
rates.(11) A trial in pulmonary tuberculosis patients in Indonesia comparing 450mg rifampin 
(10 mg/kg) to 600 mg/kg (13 mg/kg) rifampin showed a nonlinear, more than proportional 
increase of pharmacokinetic exposure.(12)  
 
The adverse effects of rifampin at the standard dose are well known, because of years of 
worldwide use since its int oduction.(13) Yet, the relationship between dose and adverse 
events is not well established and may be either toxic with a clear relation or idiosyncratic 
without such a relation.(14) There have been trials and case series that used higher doses of 
rifampin in tuberculosis and other infections such as brucellosis, leishmaniasis, Legionnaires’ 
disease, and bone and joint infections(2, 15-19) without severe adverse effects. Some 
events, such as the flu like syndrome are likely related to intermittent dosing.(20) 
 
If increasing rifampin may be more effective and could shorten therapy there is an urgent 
need to know the optimum dose. We performed a study in tuberculosis patients, therefore, 
to establish the maximum tolerated dose, to assess the incidence and severity of adverse 
events, to describe the pharmacokinetics and to measure the bactericidal effect of higher 
doses of rifampin.  
 
Some of the results of these studies have been previously reported in the form of an 
abstract. (21) 
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METHODS 
Patients  
Adults (18 to 65) with newly diagnosed, previously untreated, sputum smear-positive 
uncomplicated pulmonary tuberculosis and with no medical contraindications (see Table E1 
in the online data supplement) were included in the study. For HIV positive subjects a CD4 
count of ≥350 cells was an additional inclusion criterion. Patients were hospitalized in one of 
two study sites in Cape Town, South Africa. 
Study design   
We performed an open-label phase II multiple dose ranging study to evaluate safety, 
tolerability, pharmacokinetics and extended early bactericidal activity of increasing doses of 
rifampin.  All patients received a specified dose of rifampin for 14 days, given in 
monotherapy for the first 7 days and supplemented with standard doses of isoniazid 5 
mg/kg, pyrazinamide 25-30 mg/kg and ethambutol 15-20 mg/kg for the last 7 days. The 
patients then continued standard tuberculosis treatment (Figure 1) and had visits at 3 and 12 
weeks for clinical assessment and sputum culture for susceptibility testing.  
The first 8 patients were enrolled in a control cohort receiving 10mg rifampin/kg. 
Subsequently, patients were enrolled in consecutive intervention cohorts of 15 patients 
each. The first cohort received rifampin at a dose of 20 mg/kg. The second cohort received 
25 mg rifampin/kg, the third 30 mg rifampin/kg and the last cohort received 35 mg 
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rifampin/kg.  Of note, the consecutive dose increases for rifampin were relatively small, 
considering the non-linear pharmacokinetics of rifampin, which means that an increase in 
dose may result in an unpredictable, disproportionally larger increase in exposure.(22)  
After completion of follow-up by all subjects in each cohort, the Trial Steering Committee, 
reviewed all of the safety data for the cohort before the first patient in the next cohort was 
enrolled. Two subjects experiencing a grade 3 adverse event assessed as probably or 
definitely related to administration of high dose rifampin, or one subject experiencing a 
grade 4 or 5 adverse event assessed as definitely related to rifampin, would lead to a 
meeting of the Trial Steering Committee to discuss the continuation or termination of the 
study.(23) 
The study protocol was approved by local ethical review boards and by the Medical Control 
Council of South Africa and was conducted according to Good Clinical Practice standards. All 
patients provided written informed consent before enrolment in the study. 
The innovative design of this study differs from a classical “early bactericidal activity” study 
intended for comparison.  
Drug management 
During the 7 days of rifampin monotherapy, patients received rifampin administered as 
capsules Rifadin® (150 mg, 300 mg and /or 600 mg) from Sanofi-Aventis. Combination 
therapy of rifampin, isoniazid, pyrazinamide and ethambutol during the subsequent 7 days 
was administered in the form of the fixed dose combination (FDC) Rifafour® e-275 from 
Sanofi-Aventis, containing 150 mg rifampin, 75 mg isoniazid, 400 mg pyrazinamide and 
275 mg ethambutol per tablet. The subjects in the control group received only standard 
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Rifafour® e-275 treatment. The subjects in the other dosing groups received additional 
Rifadin® to reach the same pre-defined rifampin dose as administered in the monotherapy 
period. The exact amount of Rifafour®e-275 tablets and Rifadin® capsules was dependent on 
the dosing group of the patient and the patient’s weight before start of the study. Daily 
treatment bottles for all 14 days were prepared in advance and checked by pharmacists or 
site staff members who were licensed for dispensing.  
 
Safety and tolerability  
The primary objective of this study was to assess the maximum tolerated dose, which is 
defined as the dose below that producing unacceptable but reversible toxicity. Tolerability is 
an aspect of safety and used to indicate how well a patient is able to endure treatment such 
that adverse events do not result in the discontinuation of treatment(3). 
Symptoms assessments, physical examination, including vital signs, were performed on a 
daily base. Haematological, renal and liver function tests, glucose, uric acid and urinalysis 
and electrocardiography were scheduled at baseline and days 1, 3, 6, 10, 14 and 21 with 
appropriately narrow window periods. Adverse events were graded according to the US 
National Institute of Health Common Terminology Criteria for Adverse Events 4.0.(24) 
Patients with serious adverse events were followed up until resolution of the event. Events 
were assessed as unrelated, possibly or definitely related by site investigators (see Table E2 
in the online data supplement). 
Pharmacokinetics   
Blood samples were taken on day 7 and day 14 with a standardized meal for a full 
pharmacokinetics curve. Total (protein-bound plus unbound) plasma concentrations of 
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rifampin were measured at the Department of Pharmacy of the Radboud University Medical 
center, Nijmegen, the Netherlands, using a validated Ultra Performance Liquid 
Chromatography method with ultraviolet detection, derived from a previously described 
assay.(12) Noncompartmental pharmacokinetic analysis was performed with Winnonlin 
version 5.3 (Pharsight Corp., Mountain View, California US) to yield pharmacokinetic 
parameters, including the area under the plasma concentration-time curve (AUC0-24h or total 
exposure) and highest observed plasma concentration (Cmax), as described before.(12)  
 
Antimycobacterial activity 
Spot sputum samples were collected before enrolment, at day 19 and after 12 weeks. The 
samples were prepared for direct microscopy, stained with the auramine O method and 
presence of acid fast bacilli was scored using the IUATLD/WHO grading. Pooled overnight (16 
hours) samples were collected at baseline, daily to day 7, days 9 and 14. Each sample was 
diluted and cultured in quadruplicate on selective Middlebrook 7H11 agar plates.  Counts of 
colony forming units (CFU) were done after a minimum of 21 days of incubation to assess 
the fall of CFU over time.(25, 26) In addition, the samples were processed for culture in 
liquid broth medium according to the mycobacterial growth indicator tube (Bactec MGIT960) 
system. Time-to-positivity (TTP) was determined for each sample to assess the change in TTP 
over time. The remainder of the baseline samples were processed to determine 
susceptibility tests and an Accuprobe identification (Gen-Probe®) test was carried out to 
confirm presence of M. tuberculosis complex.  All microbiological testing was performed 
in the Department of Medical Biochemistry, Faculty of Medicine and Health Sciences, 
Stellenbosch University, Cape Town, South Africa.  
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Statistical analysis  
This was a descriptive study with no inferential statistics or hypothesis testing. The planned 
sample size of 15 patients in each group is in keeping with other trials of this type and 
accounts for the site conservative estimate of 3 dropouts per group.(3) Safety was expressed 
as incidence of adverse events by severity and relatedness. The AUC0-24h and Cmax of 
rifampin at days 7 and 14 were presented as geometric means by study group. The 
distribution of TTP on MGIT was positively skewed with log-transformed TTP more closely 
following a symmetric normal distribution. Mixed effects models with visit day as a discrete 
random effect were used to estimate the mean logCFU and logTTP in each treatment arm at 
each visit to describe the data. LogCFU of 1 or TTP of 42 days was used for negative cultures 
in this analysis. We found an unexpectedly high number of negative cultures for the short 
treatment duration. These data points would usually be excluded with standard regression 
methods due to the quantitative measure of logCFU or TTP being below or above the limit of 
detection. In order to include these censored observations, Tobit regression(27) was used to 
estimate the 14-day early bactericidal activity, accounting for negatives cultures using a 
lower limit of detection censoring for logCFU of 1 and an upper limit for TTP of 42 days. 
Separate models were fitted for each patient with parameter estimates summarised by 
treatment group using a random effects model accounting for within- and between- patient 
variability. Linear regression was used to explore the relationship between 14-day early 
bactericidal activity and each of actual dose received in mg, actual dose received in mg/kg 
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and exposures achieved (AUC0-24 and Cmax) comparing models using the proportion of 
variation explained, R
2
. 
 
 
RESULTS 
Patients 
A total of 68 culture positive pulmonary tuberculosis patients were recruited between June 
2011 and April 2012 with the last patient completing follow-up in August 2012. Patient 
characteristics are shown in Table 1.  
Safety/tolerability 
The stopping criteria were not met and the Trial Steering Committee recommended that the 
trial continued after data safety review at the end of each cohort. None of the patients 
discontinued or were withdrawn from the study. There were a total of 163 adverse events: 
128 grade 1, 30 grade 2, and 5 grade 3 adverse events. No grade 4 and 5 adverse events 
occurred. 53 adverse events were unrelated to rifampin, 102 were “possibly” related and 8 
were assessed to be “definitely” related to rifampin (Table 2).  
The most common adverse events related to monotherapy with rifampin were abdominal 
pain, vomiting, headache, and pruritus. The most common adverse events related to the 
combination treatment with rifampin, isoniazid, pyrazinamide and ethambutol were 
vomiting, headache, hyperuricaemia, pain in the extremities and pruritus. These adverse 
events occurred in all groups and were not attributable to a specific dose group.  
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Pharmacokinetics 
The average AUC0-24 and Cmax values of rifampin at day 14 are presented in Table 3. Upon 
doubling the dose of rifampin from 10 mg/kg to 20 mg/kg, the geometric mean AUC0-24  of 
rifampin increased more than four-fold, which reflects a more than dose-proportional 
increase of exposure with the dose. No ceiling in rifampin AUC0-24 or flattening of the 
relationship between dose administered and AUC0-24 achieved was observed. Strong 
increases in average rifampin Cmax with the dose were also observed (Table 3). Of note, 
large interindividual variability in  AUC0-24h and Cmax was observed (Table 3 and Figure 2), yet 
the minimum exposure recorded in each group (either in terms of AUC0-24h or Cmax) increased 
with the dose administered.   
Antimycobacterial activity  
One patient in the 20 mg/kg group was negative on solid media at all but one sample and 
these data were therefore removed from all analyses. The fall in bacterial load in sputum 
over time expressed as CFU and TTP is summarized in Figure 3. The highest doses of 30 and 
35 mg/kg show highest 14-day early bactericidal activity on both CFU and TTP (Figure 4).  
There was no clear biphasic curve from days 7-14 after which the other drugs, including 
isoniazid were added. At 14 days, 8 of 14 patients in the 35mg/kg group were culture 
negative on solid media as compared to 3 of 8 in the control group, 5 of 14 in the 20 mg/kg 
group, 0 of 15 in the 25 mg/kg and 2 of 15 in the 30 mg/kg group. 
AUC0-24h at day 14 was a better predictor of 14-day early bactericidal activity on CFU 
(R
2
=0.12) than dose in mg/kg received (R
2
=0.06) or the dose in mg (R
2
=0.05), although the 
proportion of explained variance was low. AUC0-24h was a marginally better predictor of 14-
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day early bactericidal activity on TTP (R
2
=0.19) than dose in mg/kg received (R
2
=0.18) or the 
dose in mg (R
2
=0.12). 
 
 
DISCUSSION 
This study shows that doses of rifampin that are considerably higher than the standard dose 
are safe and well tolerated. As accumulating evidence indicates that higher doses of and 
increased exposures to rifampin are more efficacious in tuberculosis treatment, (5-7, 10, 11, 
28, 29) we believe that this finding may change the landscape of treatment for drug 
susceptible tuberculosis and may permit shortening of the duration of treatment, as rifampin 
is a very strong sterilizer. In addition, there is evidence that an important driver behind the 
emergence of multidrug-resistant tuberculosis is low exposures of especially rifampin caused 
by inter-individual pharmacokinetic variability. (4, 30, 31) The current standard dose of 
rifampin used in the last 40 years is probably considerably too low in many patients.  
  
The primary objective of this study was to estimate the maximum tolerated dose of rifampin 
and it was significant that dose-limiting toxicities were not found at the highest administered 
dose of 35 mg/kg daily. Higher doses than 35 mg/kg were not planned before the study, as 
very high exposures to rifampin were anticipated at this dose and the study did not have 
unrestricted funding.  
The pharmacokinetic behaviour of rifampin over the range of increasing doses was more 
than dose-proportional, “super-proportional”. The average AUC0-24 at 35 mg/kg was almost 
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10-fold higher than the average exposure at 10 mg/kg rifampin. This phenomenon was 
previously described in other studies for lower doses.(12, 22) We did not observe a ceiling 
effect as was reported in the pharmacokinetics of one of the other promising rifamycins, 
rifapentine.(32) Importantly, apart from average exposures, the lowest observed AUC0-24h 
and Cmax values also increased, with almost every dose step (Table 3 and Figure 2). This is 
what we aimed for, as it is probably the lowest exposures that cause treatment failures and 
relapses thereby preventing treatment shortening. In addition, these low exposures may 
favor the emergence of resistance.(4, 30, 31) We showed, however, that there was a large 
inter-individual variation in pharmacokinetics (Figure 2). This is a warning for further studies 
of high doses of rifampin, as individual exposures may be much higher than our observed 
means. This may have a beneficial effect in terms of efficacy, but may also cause an 
increased risk of toxicity. 
There was a greater estimated fall in bacterial load in the higher dosing groups dose as 
measured by a larger fall in CFUs over time and by a more rapid increase in TTP over time.  
This study was not powered for efficacy and these differences were not statistically 
significant. Although this result is encouraging, the finding may not necessarily indicate 
increased efficacy in terms of treatment failure and relapse, the definitive patient-relevant 
outcomes and phase III endpoints. In mouse models, however, there is evidence that higher 
doses of rifampin sterilize and cure the mice in a shorter period of time.(5-7) Additionally, in 
a recent clinical trial in Indonesian tuberculous meningitis patients higher doses of rifampin 
(around 13 mg/kg intravenously as compared to around 10 mg/kg orally) led to a decreased 
6 months mortality of roughly 50 %.(33) 
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By design, small numbers of patients selected on the basis of very strict criteria were treated 
for only a short period of time with higher doses of rifampin. Therefore, our findings need to 
be confirmed in longer phase II studies with less narrow inclusion criteria and adequate 
patients numbers before being tested in a phase III study. Currently, two studies have 
started with this objective. The first randomized controlled trial has recently finished 
enrolment (ClinicalTrials.gov NCT00760149) and compared a control group with the 
standard tuberculosis regimen with two groups of 15 mg rifampin/kg and 20 mg rifampin/kg 
combined with isoniazid, pyrazinamide and ethambutol for two months in groups of 50 
patients each. The second study with a multi arm multi stage (MAMS) design performed 
within the PanACEA consortium (ClinicalTrials.gov  NCT01785186) compares a standard 
control group with a group on 20 mg rifampin/kg combined with moxifloxacin, isoniazid and 
pyrazinamide, a group with 20 mg rifampin/kg combined with the new compound SQ109(34) 
and isoniazid and pyrazinamide, and a group with 35 mg rifampin/kg combined with 
isoniazid, pyrazinamide and ethambutol for three months. A further two month study is 
evaluating 15 mg rifampin/kg and 20 mg rifampin/kg in Peru (ClinicalTrials.gov 
NCT01408914). Depending on the results of these trials, we are planning to extend the study 
in this paper and increase the dose until the actual maximum tolerated dose is reached.  
In conclusion, higher doses of rifampin up to 35 mg/kg were safe and well tolerated for two 
weeks. The higher doses of rifampin achieved up to 10-fold higher average exposures in 
plasma, due to nonlinear “super-proportional” pharmacokinetic behaviour. The greater 
estimated fall in bacterial load measured by CFUs and TTP suggests an increased efficacy in 
the higher dosing groups supporting the idea that this critical drug is being administered at 
too low a dose. With the results of phase IIB studies currently underway that further 
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examine these higher dose, we should look forward to a pivotal phase III trial to definitely 
answer the question what the right dose of rifampin is. 
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                            All                             10 mg                         20 mg                    25 mg                       30 mg                           35 mg                                                          
                              Subjects                       RIF/kg                         RIF/kg                   RIF/kg                        RIF/kg                         RIF/kg                                                                                         
__________________________________________________________________________________________ __________                                           
                                                                                                                                                   
N                                  68                                8                               15                          15                               15                               15    
 
Age (yr)                                                                                                                                                                                                                                                                           
 Median                     30.5                             27.5                         27.0                        25.0                        40.0                              37.0                                                          
 Range                      18-59                           19-49                       18-46                     19-46                     19-59                           21-59                                                            
 
Weight (kg)                                                                                                                                                                                                                                                                                     
 Median                      53.6                            56.9                         52.5                         52.8                        54.0                              57.0                                                         
Range                      40.2-84.2                   46.8-64.9                41.8-62.7                 40.2-67.9               45.7-84.2                   40.5-74.0                                                          
                                                                                                                                                                                                                                                                                             
Body-Mass Index (kg/m^2)                                                                                                                                                                                                                                                                                    
 Median                      19.4                             20.5                        18.4                          19.3                        20.9                            19.5                                                         
 Range                      14.7-30.9                   15.8-26.3               16.8-26.2                 15.1-25.2              16.4-30.9                    14.7-25.2    
 
Male sex no.              48 (71)                         6 (75)                     11 (73)                     10 (67)                   11 (73)                       10 (67)                  
 
Race –no (%)                                                                                                                                                  
 Black                           28 (41)                        3 (38)                      7 (47)                        4 (27)                    9 (60)                          5 (33)                                           
 Coloured                    40 (59)                        5 (63)                      8 (53)                       11(73)                    6 (40)                         10  (67)                      
  
HIV-positive (%)          1(1,5)                          1 (13) 
 
Baseline log10CFU/ml median  
            (range)                                                  4.88                        4.00                          5.39                            4.58                       4.39
                                    (2.15-5.85)           (negative*-5.82)          (3.70-6.38)               (2.68-6.25)         (2.86-5.82) 
Baseline TTP / days median                        6.04     7.35  6.75  8.08                 8.22 
             (range)              (4.15 - 12.17)              (4.44-13.33)             (5.00-10.69)           (4.81-13.46)        (4.75-20.04) 
 
Table1. Demographic and baseline characteristics at inclusion. * One patient on 20mg/kg group was negative on solid 
media at all but one visit and their data was therefore removed from all analyses.  
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Group Total Grade 1 Grade 2 Grade 3 * 
Relatedness  Possibly 
related 
Related Possibly 
related 
Related Possibly 
related 
Related 
10 mg/kg 
(control) 
7 0 0 0 0 0 0 
20 mg/kg 
RIF 
39 21 1 4 0 2 0 
25 mg/kg 
RIF 
24 11 2 2 0 0 0 
30 mg/kg 
RIF 
39 21 3 4 0 1 0 
35 mg/kg 
RIF 
54 27 2 9 0 0 0 
Total 
 
163 80 8 19 0 3 0 
 
Table 2. Possibly related and definitely related adverse events per grade and per dose group *Among the grade 3 
events there was a case of transient hyperkalemia of 6.1 mmol/L  in the 20 mg/kg RIF group that reoccurred in 
the same patient in week 3 (counted as two events). Potassium values normalized with no specific measures 
and no ECG changes were recorded. In the 30 mg/kg RIF group there was one grade 3 unrelated pleural 
effusion and a possibly related elevation of transaminase more than five times the upper limit of normal, which 
normalized spontaneously after repeat measurements. No grade 4 or grade 5 events were observed.  
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Group AUC0-24h (h*mg/L) * Cmax (mg/L) # 
10 mg/kg (control)  26.3  (21.3 – 40.9)    7.4   (6.1 – 9.9) 
20 mg/kg 113    (77.5 – 162)  21.6  (16.0 – 31.9) 
25 mg/kg 135    (91.5 – 228)  25.1  (16.3 – 34.6) 
30 mg/kg 190    (84.7 – 436) 33.1  (17.6 – 55.8) 
35 mg/kg 235    (166 – 321)  35.2  (28.6 - 44.2) 
 
Table 3. Steady state PK of RIF (day 14) Geometric means and range *AUC0-24h : area under the time versus concentration 
curve up to 24 h post dose, Cmax: peak plasma concentration 
  
#
  Serial venous blood samples were taken just prior to and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours after the 
investigational products were taken under direct supervision and with  a standardized meal 
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Legends Figures 
 
Figure 1. Schematic overview of the study design 
In each study group, monotherapy of rifampin for 7 days was administered using Rifadin® from Sanofi-Aventis 
in 150 mg capsules, 300 mg tablets or 600 mg tablets. The combination of capsules and tablets for each patient 
was adjusted to achieve the correct dose by weight. In the subsequent period of 7 days, patients received a 
fixed dose combination tablet Rifafour e-275, containing 150 mg rifampin, 75 mg isoniazid, 400 mg 
pyrazinamide and 275 mg ethambutol, combined with additional rifampin (i.e. Rifadin) to reach the same 
pre-defined rifampin dose in mg/kg as administered in the monotherapy period. Starting from day 15 the 
patients were administered Rifafour e-275 only. All study medication was taken in the morning with a light 
breakfast and a glass of water. Administration of tuberculosis drugs was witnessed by site staff and a hand-and-
mouth procedure was performed to check for drug intake at every occasion.  
 
 
Figure 2. Distribution of exposure to rifampin (AUC0-24h) at day 14 in the various rifampin 
dosing groups . The reference line mimics a linear relationship. 
 
 
Figure 3. Fitted estimates of differences from mean baseline log10 CFU (upper panel) and 
log10TTP/ml (lower panel) by visit and treatment arm 
 
Figure 4. Early bactericidal activity of rifampin based on CFU (upper panel) and TTP (lower 
panel) per day  
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Table E1. Detailed inclusion and exclusion criteria 
Inclusion Criteria 
Participants are required to meet all of the following inclusion criteria in order to be 
randomized: 
1. Provide written, informed consent prior to all trial-related procedures including HIV 
testing.  
2. Male or female, aged between 18 and 64 years inclusive. 
3.  Body weight (in light clothing and with no shoes) between 40 and 90 kg, inclusive. 
4. Newly diagnosed, previously untreated, uncomplicated, sputum smear-positive, 
pulmonary tuberculosis. 
5. A chest X-ray picture which in the opinion of the Investigator is compatible with 
tuberculosis. 
6. Sputum positive on direct microscopy for acid-fast bacilli (at least 1+ on the 
IUATLD/WHO scale (Appendix 3)).  
7. Ability to produce an adequate volume of sputum as estimated from a spot assessment 
(estimated 10 ml or more overnight production).  
8. Female participants of childbearing potential must have a negative serum pregnancy test 
and agree to use a highly effective method of birth control (i.e. two of the following 
precautions: tubal ligation, vaginal diaphragm, intrauterine device, condom or sponge 
with spermicide, oral contraceptives, contraceptive implant, combined hormonal patch, 
combined injectable contraceptive or depot-medroxyprogesterone acetate, partner(s) 
has had a vasectomy) throughout the participation in the trial and for 1 week after last 
dose, unless she and her partner(s) are sterile (that is, women who have had a bilateral 
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oophorectomy and/or hysterectomy or have been postmenopausal for at least 
12 consecutive months; men who have had bilateral orchidectomy). 
9. Male participants must agree to use an adequate method of contraception (double 
barrier) throughout participation in the trial and for 12 weeks after last dose, unless he 
and his partner(s) are sterile (that is, women who have had a bilateral oophorectomy 
and/or hysterectomy or have been postmenopausal for at least 12 consecutive months; 
men who have had bilateral orchidectomy). 
Exclusion Criteria 
Participants will be excluded if they meet any of the following exclusion criteria prior to 
randomization: 
1. Poor general condition where any delay in treatment cannot be tolerated per discretion 
of Investigator. 
2. Rifampin-resistant and/or Isoniazid-resistant bacteria detected with a sputum specimen 
collected within the pre-treatment period and tested at the study laboratory. 
3. Treatment received with any drug active against Mycobacterium tuberculosis within the 
3 months prior to Visit 1 (isoniazid, ethambutol, amikacin, cycloserine, rifabutin, 
rifampin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, pyrazinamide, 
thioacetazone, capreomycin, quinolones, thioamides, metronidazole). 
4. A history of allergy to the IMP or related substances.  
5. Clinically significant evidence of extrathoracic tuberculosis (miliary tuberculosis, 
abdominal tuberculosis, urogenital tuberculosis, osteoarthritic tuberculosis, tuberculous 
meningitis), as judged by the investigator. 
6. A history of previous tuberculosis.  
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7. Evidence of serious lung conditions other than tuberculosis or uncontrolled obstructive 
bronchial disease.  
8. History of lens opacity or evidence of lens opacity on slit lamp ophthalmologic 
examination. 
9. Any evidence of renal impairment, including but not limited to serum creatinine levels 
above the upper limit of the laboratory reference range, or hepatic impairment 
characterized by alanine aminotransferase (ALT) and/or aspartate transferase (AST) 
levels >3 times the upper limit of the laboratory reference range.  
10. For males, any evidence or history of abnormality in the reproductive system, including 
but not limited to any one or more of the following: serum testosterone, luteinizing 
hormone (LH), and/or follicle-stimulating hormone (FSH) levels outside the laboratory 
reference range. 
11. History and/or presence (or evidence) of neuropathy or epilepsy.  
12. Clinically relevant changes in the ECG such as atrioventricular (AV) block, prolongation of 
the QRS complex over 120 milliseconds, or of either the QTcF or QTcB interval over 
450 milliseconds on the screening ECG. 
13. A history of or current clinically relevant cardiovascular disorder such as heart failure, 
coronary heart disease, hypertension, arrhythmia, tachyarrhythmia or status after 
myocardial infarction. Family history of sudden death of unknown or cardiac-related 
cause, or of prolonged QTc interval. Concomitant use of any drug known to prolong QTc 
interval (including amiodarone, bepridil chloroquine, chlorpromazine, cisapride, 
clarithromycin, disopyramide dofetilide, domperidone, droperidol, erythromycin, 
halofantrine, haloperidol, ibutilide, levomethadyl, mesoridazine, methadone, 
pentamidine, pimozide, procainamide, quinidine, sotalol, sparfloxacin, thioridazine). 
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14. Diabetics using insulin.  
15. Evidence of clinically significant metabolic, gastrointestinal, neurological, psychiatric or 
endocrine diseases, malignancy, or other abnormalities (other than the indication being 
studied).  
16. Any diseases or conditions in which the use of the standard tuberculosis drugs or any of 
their components is contra-indicated, including but not limited to allergy to any 
tuberculosis drug, their component or to the IMP.  
17. Any disease or conditions in which any of the medicinal products listed in the section 
pertaining to prohibited medication is used.  
18. Known or suspected, current or history of within the past 2 years, alcohol or drug abuse, 
that is, in the opinion of the investigator, sufficient to compromise the safety or 
cooperation of the patient.   
19. Administration of an IMP prior to Visit 1, within 5 half-lives for that IMP if known. If the 
half-life of the IMP is unknown within 1-month. 
20. Pregnant, breast-feeding, or planning to conceive or father a child within twelve weeks 
of cessation of treatment for males and within one week of cessation of treatment for 
females. 
21. Use of any drugs or substances within 30 days prior to dosing known to be strong 
inhibitors or inducers of cytochrome P450 enzymes (including xenobiotics, quinidine, 
tyramine, ketoconazole, testosterone, quinine, gestodene, metyrapone, phenelzine, 
doxorubicin, troleandomycin, cyclobenzaprine, erythromycin, cocaine, furafylline, 
cimetidine, dextromethorphan).  Exceptions may be made for participants that have 
received 3 days or less of one of these drugs or substances, if there has been a wash-out 
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period before administration of IMP equivalent to at least 5 half-lives of that drug or 
substance.      
22. Use of any therapeutic agents known to alter any major organ function (e.g., 
barbiturates, opiates, phenothiazines, cimetidine) within 30 days prior to dosing.   
23. Use of glucocorticoids within  one year prior to dosing.   
24.  HIV infection with helper/inducer T-lymphocyte (CD4 cell) count of ≤ 300×10
-6
/L.  
25. Receiving antiretroviral therapy (ART). 
All inclusion and no exclusion criteria must be met. If no single variable/value is outside of 
the ranges of acceptability, but when multiple values are close to the limits and/or whenever 
the Principal Investigator has reason to suspect that there might be a health problem (other 
than tuberculosis), enrolment should only be considered after discussing the case with the 
sponsor medical monitor. 
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Table E2 Definitions of relatedness used to assess adverse events 
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